Cancer: Curenetics.Io Innovates Tech-Driven Methods To Help Meet NHS Cancer Survival Targets
Curenetics.io has been developing an AI platform that has had encouraging results that will speed up early diagnosis. This is driven through our AI-based E11even cancer blood-based diagnostic test. This could be deployed in primary care and help triage the cancer diagnostic pathway for 11 common, killer cancers. We also have our medical software, CIT-AI, which is able to predict a patient’s response to cancer immunotherapy treatment. Immunotherapy has revolutionised the treatment of many cancers but they could be very expensive
Is the NHS open to new technology?
Invitation to a dinner at the Spectator’s offices, sponsored by Phillips healthcare. It was a brainstorming session on how technology could transform Healthcare, particularly in the NHS. Dinner was attended by entrepreneurs, doctors and healthcare experts discussed how new technology could ease pressure on the NHS – and whether the health service was equipped to take advantage of it.
Guests included: Naushard Jabir, founder and CEO of Vida, Paul Bate, Director of NHS Services at Babylon, Professor Simon Wessely, President of the Royal Society of Medicine, Helen Whately MP, Dr Claire Novorol, chief medical officer at Ada, Neil Mesher, CEO of Philips UK and Ireland, Sola Adeleke of Curenetics ( formerly Aurora Medical Innovation), Nicholas Timmins, senior fellow at the King’s Fund and Dr Jakobsen, chief scientific officer of Immunocore and Adaptimmune. Fraser Nelson chaired the discussion.